Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Unrelated Cord Blood Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE INCLUSION CRITERIA:~In general this encompasses all haematological disorders where a volunteer unrelated donor transplant is clinically indicated.~1. Acute, chronic leukaemia or myelodysplastic syndrome for which allogeneic transplantation is considered as the best treatment option.~   1. Acute myeloid leukaemia (AML) in first complete remission (CR1) with one of the following characteristics:~      * High risk cytogenetic or molecular alterations (e.g. t(9;22), deletion 7/7q-, monosomy 5 or del(5q), 3q26 alterations, complex karyotype \[3 or more anomalies\], p53 alterations, 11q23 especially t(6;11) abnormalities, FLT-3 ITD)~     * Leukocytes at diagnosis \> 50 x109/l (except in cases with good prognosis molecular rearrangements for which leukocytes should be \> 100 x 109/l)~  2. Myelodysplastic syndromes~      * International Prognosis Index (IPSS) above 1 (intermediate group 2 or high risk)~     * IPSS 0 or 0.5 in the presence of cytopenias requiring treatment.~  3. Therapy related AML or MDS in first CR~  4. AML or MDS in second (CR2) or subsequent CR~  5. Ph'-positive chronic myeloid leukaemia~   i. In first chronic phase if refractory and/or intolerance to tyrosine kinase inhibitors is clearly demonstrated ii. In second chronic phase~2. Acute lymphoblastic leukaemia (ALL)~   a. In CR1 with one of the following characteristics: i. Very high risk chromosome or molecular alterations (e.g. t(9;22), t(4;11), complex karyotype in adults, bcr/abl rearrangements, MLL rearrangements) ii. Slow response to induction treatment defined as the presence of \>10% blasts in bone marrow at day 14 of induction treatment iii. Adults aged \> 30 years iv. Adults with B ALL cell line with a number of leukocytes at diagnosis \>25 x 109/L or T ALL cell line with a number of leukocytes at diagnosis \>100X109/L~   b. In CR2 or subsequent CR~3. Non-Hodgkin's lymphoma~   1. Follicular NHL: in second or subsequent complete or partial remission~  2. Mantle cell NHL: in second or subsequent complete or partial remission~  3. High grade NHL: in second complete or very good partial remission~4. Hodgkin's disease~   a. in second or subsequent complete or partial remission~5. Chronic lymphocytic leukaemia.~   1. in second or subsequent remission~  2. with adverse risk prognostic features in first remission~6. Acquired bone marrow failure syndromes~7. Other haematological malignancies for which UD bone marrow transplantation is indicated~PATIENT SELECTION~Inclusion criteria: myeloablative conditioning regimen~1. Aged under 35 years and greater than 18 years~2. Absence of HLA compatible related donor.~3. Need for an urgent transplantation or absence of HLA-compatible VUD after searching the international registries.~4. Patients with a HLA-compatible VUD but whose donor is considered by the transplantation centre as unsuitable will also be eligible.~5. Availability of suitable UD-UCB unit/s.~6. Informed consent.~Exclusion criteria: myeloablative conditioning regimen~1. Patients with an available 5-6/6 HLA-A, -B, -DRB1 matched sibling donor or 10/10 unrelated bone marrow donor~2. ECOG performance status worse than 2~3. Cardiac insufficiency requiring treatment, symptomatic coronary artery disease or LVEF less than 40%.~4. Hepatic disease, with total bilirubin above 20umol/l or AST \> 3 times upper limit of normal.~5. Severe hypoxaemia, pO2 \< 70 mm Hg, with decreased DLCO \< 70% of predicted; or mild hypoxemia, pO2 \< 80 mm Hg with severely decreased DLCO \< 60% of predicted.~6. Impaired renal function (creatinine \> 2 times upper limit of normal or creatinine clearance \< 50% for age, gender, weight).~7. Patients who have received previous treatment with Thymoglobulin®~8. HIV or HTLV positive patients.~9. Female patients who are pregnant or breast feeding due to risks to foetus from conditioning regimen and potential risks to nursing infants.~10. Life expectancy severely limited by diseases other than the disease indication for transplant~11. Serious concurrent untreated infection e.g. active tuberculosis, mycoses or viral infection~12. Serious psychiatric/ psychological disorders~13. Absence of /inability to provide informed consent~14. Serious diseases that prevent treatments with chemotherapy~15. Myelofibrosis~Inclusion criteria: reduced-intensity conditioning regimen (For both FluMel \& FluCyTBI regimens):~1. Age under 70 years and older than 18 years~2. Absence of HLA compatible related donor.~3. Need for an urgent transplantation or absence of HLA-compatible VUD after searching the international registries.~4. Patients with a HLA-compatible VUD but whose donor is considered by the transplantation centre as unsuitable will also be eligible.~5. Availability of suitable UD-UCB unit/s.~6. Informed consent.~Exclusion Criteria: reduced-intensity conditioning regimen (For both FluMel \& FluCyTBI regimens):~1. Patients with an available 5-6/6 HLA-A, -B, -DRB1 matched sibling donor or 10/10 unrelated bone marrow donor~2. ECOG performance status worse than 2~3. Cardiac insufficiency requiring treatment, symptomatic coronary artery disease or LVEF less than 35%.~4. Hepatic disease, with total bilirubin greater than 2 times upper limit of normal or AST \> 5 times upper limit of normal.~5. Severe hypoxaemia, pO2 \< 70 mm Hg, with decreased DLCO \< 50% of predicted; or mild hypoxemia, pO2 \< 80 mm Hg with severely decreased DLCO \< 50% of predicted.~6. Impaired renal function (creatinine \> 2 times upper limit of normal or creatinine clearance \< 50% for age, gender, weight).~7. Previous irradiation that precludes the safe administration of an additional dose of 200 cGy of total body irradiation (TBI).~8. Patients who have received previous treatment with Thymoglobulin®~9. HIV or HTLV positive patients.~10. Female patients who are pregnant or breast feeding due to risks to foetus from conditioning regimen and potential risks to nursing infants.~11. Life expectancy severely limited by diseases other than the disease indication for transplant~12. Serious concurrent uncontrolled infection e.g. active tuberculosis, mycoses or viral infection~13. Serious psychiatric/ psychological disorders~14. Absence of /inability to provide informed consent~15. Within 6 months of prior myeloablative transplant.~16. Patients with acute leukaemia in morphological relapse/ persistent/ progressive disease~17. Intermediate or high grade NHL, mantle cell NHL and Hodgkin's disease that is refractory or progressive on salvage therapy.~18. Myelofibrosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Myeloblative conditioning regimen (Type: OTHER): None
- Reduced intensity conditioning regimen - FluCyTBI (Type: OTHER): None
- Reduced intensity conditioning regimen - FluMel (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues